drugset

drugset / Trial / NCT07532655

A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants

NCT07532655 ↗

Phase 1 Not yet recruiting 44 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and tolerability of single dose of SYH2082 Injection in healthy participants.

Timeline

Start: 2026-04-14
Primary completion: 2026-10-28
Completion: 2027-02-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SYH2082	Unknown	—	Subcutaneous

Indications